Actuate Therapeutics’ (ACTU) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Actuate Therapeutics (NASDAQ:ACTU) in a report issued on Wednesday morning,Benzinga reports. They currently have a $15.00 target price on the stock.

Several other brokerages have also issued reports on ACTU. Wall Street Zen raised Actuate Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, April 4th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Actuate Therapeutics in a research report on Friday, March 27th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $17.50.

Actuate Therapeutics Stock Performance

Shares of ACTU opened at $2.97 on Wednesday. Actuate Therapeutics has a 52-week low of $1.58 and a 52-week high of $11.99. The business’s 50 day moving average price is $2.81 and its two-hundred day moving average price is $5.10. The firm has a market cap of $70.42 million, a PE ratio of -2.83 and a beta of 0.85.

Actuate Therapeutics (NASDAQ:ACTU) last issued its quarterly earnings results on Thursday, March 26th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.06. Research analysts predict that Actuate Therapeutics will post -0.8 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Voss Capital LP grew its stake in shares of Actuate Therapeutics by 213.2% during the 3rd quarter. Voss Capital LP now owns 896,278 shares of the company’s stock worth $5,996,000 after acquiring an additional 610,138 shares during the period. BIOS Capital Management LP grew its stake in shares of Actuate Therapeutics by 0.9% during the 3rd quarter. BIOS Capital Management LP now owns 10,049,996 shares of the company’s stock worth $67,234,000 after acquiring an additional 84,917 shares during the period. Wells Fargo & Company MN grew its stake in shares of Actuate Therapeutics by 48.8% during the 4th quarter. Wells Fargo & Company MN now owns 20,146 shares of the company’s stock worth $123,000 after acquiring an additional 6,604 shares during the period. Jane Street Group LLC bought a new position in shares of Actuate Therapeutics during the 4th quarter worth $102,000. Finally, Deutsche Bank AG grew its stake in shares of Actuate Therapeutics by 640.0% during the 4th quarter. Deutsche Bank AG now owns 9,309 shares of the company’s stock worth $57,000 after acquiring an additional 8,051 shares during the period.

About Actuate Therapeutics

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.